Budget Amount *help |
¥33,150,000 (Direct Cost: ¥25,500,000、Indirect Cost: ¥7,650,000)
Fiscal Year 2016: ¥10,660,000 (Direct Cost: ¥8,200,000、Indirect Cost: ¥2,460,000)
Fiscal Year 2015: ¥10,660,000 (Direct Cost: ¥8,200,000、Indirect Cost: ¥2,460,000)
Fiscal Year 2014: ¥11,830,000 (Direct Cost: ¥9,100,000、Indirect Cost: ¥2,730,000)
|
Outline of Final Research Achievements |
In this study, we developed several types of novel recombinant adenoviruses (Ad) for the treatment, prevention, and diagnosis of diseases. We developed Cas9-expressing adenovirus vector for genome editing. We analyzed the mechanism how intramuscular vaccination of an adenovirus vector promotes the induction of antigen-specific gut-mucosal CTLs. We also developed a novel detection system of circulating tumor cells using a green fluorescence protein-expressing conditionally replicating adenovirus.
|